entsAdd a shortcutMore TranslateBooksWalletShoppingBloggerFinancePhotosMy BusinessShareChange photoRene Matos [email protected]–PrivacyView profileSign outHidden fieldsAdvanced Patent SearchPatentsPublication numberUS5676977 APublication typeGrantApplication numberUS 08/658,955

Publication dateOct 14, 1997Filing dateMay 31, 1996Priority dateSep 22, 1994Fee statusLapsedAlso published n number08658955, 658955, US5676977 A, US 5676977A,US-A-5676977,US5676977 A,US5676977AInventorsMarvin S. AntelmanOriginal AssigneeAntelman TechnologiesLtd.Export CitationBiBTeX, EndNote, RefManPatent Citations (10), Non-Patent Citations (2),Referenced by (11), Classifications (5), Legal Events(8)External Links: USPTO, USPTO Assignment,EspacenetMethod of curing AIDS with tetrasilver tetroxide molecular crystaldevicesUS 5676977 A

ABSTRACTThe diamagnetic semiconducting molecular crystal tetrasilver tetroxide (Ag 4 O4) is utilized for destroying the AIDSvirus, destroying AIDS synergistic pathogens and immunity suppressing moieties (ISM) in humans.A single intravenous injection of the devices is all that is required for efficacy at levels of about 40 PPM of humanblood. The device molecular crystal contains two mono and two trivalent silver ions capable of "firing" electronscapable of electrocuting the AIDS virus, pathogens and ISM. When administered into the bloodstream, the deviceelectrons will be triggered by pathogens, a proliferating virus and ISM, and when fired will simultaneously trigger aredox chelation mechanism resulting in divalent silver moieties which chelate and bind active sites of the entitiesdestroying them. The devices are completely non-toxic. However, they put stress on the liver causinghepatomegaly, but there is no loss of liver function.IMAGES(4)

CLAIMS(3)What is claimed is:1. A method of treating AIDS-afflicted humans comprising injecting a multitude of tetrasilver tetroxide molecularcrystals into the bloodstream of the human subject.2. A method for increasing white blood cell counts in AIDS-afflicted humans comprising injecting a multitude oftetrasilver tetroxide molecular crystals into the bloodstream of the human subject.3. Methods of treating AIDS-affilicted humans according to claims 1-2 where the concentration of saidmolecular crystals is approximately 40 PPM of the total blood weight of the human subject.DESCRIPTIONThis application is a continuation-in-part of patent application Ser. No. 08/310,859 filed Sep. 22, 1994, nowabandoned.BACKGROUND OF THE INVENTIONThe present invention relates to the employment of molecular crystals as anti-AIDS devices, but more particularlyto the molecular crystal semiconductor tetrasilver tetroxide Ag4 O4 which has two monovalent and two trivalentsilver ions per molecule, and which through this structural configuration enables intermolecular electron transfercapable of killing viruses and binding them to the resulting silver entity so that a single intravenous injection willcompletely obliterate acquired immune deficiency syndrome (AIDS) in humans. Furthermore, said devices arecapable of killing pathogens and purging the bloodstream of immune suppressing moieties (ISM) whether or notcreated by the AIDS virus (HIV); so as to restore the immune system.The present invention is based on concepts previously elucidated in applicant's U.S. Pat. No. 5,336,499 whichdiscloses the destruction and inhibition of bacteria, algae and the AIDS virus in nutrient life supporting systems by

using said silver oxide devices. Example 3 of said patent discloses that 18 PPM of said crystal devices could totallysuppress the AIDS virus (page 6, line 5). Subsequent to the filing of the aforementioned patent, further testingrevealed complete 100% destruction of the AIDS virus in vitro at 20 PPM, and the fact that said devices wereharmless when ingested and inhaled, being non-toxic.Encouraged by these evaluations and successes, applicant obtained permission to evaluate the crystals in vitroagainst murine acquired immune deficiency syndrome (MAIDS). Only one facility in the State of Israel is licensedfor these evaluations, namely, the Kaplan Hospital in Rehovot, Israel, which is affiliated with the Hebrew UniversityHadassah Medical School where said evaluations were done.The initial evaluations entailed experimenting with various silver moieties cited in applicant's aforementionedpatent, concentrations, non-reactive buffers and modes of administration. After about 18 months of judicious effortsand initial failures, success was finally achieved in destroying the MAIDS virus in C57BL mice with a singleintravenous injection. The results of this test program comprise Example 5 of U.S. Pat. No. 5,336,499. Aftersuccess with mice, the inventor was able to test the efficacy of said devices on two select etiological groups ofterminal AIDS patients in a clinic in Tegucigalpa, Honduras, Central America.The AIDS patients comprised the etiological subgroups, Candidiasis and Wasting Syndrome. Current indicatordiseases for diagnosing AIDS which have been expanded by the CDC, fall into the following five major categorieswith the approximate percent distribution among AIDS patients:1. P. carinii pneumonia19%3. Candidiasis13%4. Kaposi's sarcoma51%2. Wasting syndrome11%5. Dementia6%This invention concerns itself with the treatment and cure of candidiasis and wasting syndrome AIDS patients withTetrasil*. These two groups account for approximately one third of AIDS cases.Stedman's Medical Dictionary (Williams & Wilken's 26th Ed., 1995) defines wasting syndrome "as a condition of10% weight loss in conjunction with diarrhea or fever . . . Associated with AIDS (p. 1744)."OBJECTS OF THE INVENTIONThe main object of the invention is to provide for a molecular scale device of a single tetrasilver tetroxide crystallinemolecule capable of restoring the immunity of AIDS afflicted humans of the two AIDS etiological subgroups,candidiasis and wasting syndrome.Another object of the invention is to provide for immunity restoration in said AIDS afflicted humans through a singleinjection.

Another object of this invention is to destroy ISM in humans manifesting AIDS diseases of said AIDS etiologicalsubgroups irrespective as to whether said ISM was HIV induced, since it is known that humans may manifest AIDSand still be HIV negative, and thus restore the immune system in said humans.Another object of this invention is to destroy the AIDS virus when present in the systems of said AIDS afflictedhumans.SUMMARY OF THE INVENTIONThis invention relates to a molecular scale device not only capable of destroying the AIDS virus, but of purging thehuman bloodstream of pathogens and restoring immunity to AIDS patients of the candidiasis and wastingsyndrome categories. Said molecular device consists of a single crystal of tetrasilver tetroxide (Ag 4 O4). The crystallattice of this molecule has a unique structure since it is a diamagnetic semiconducting crystal containing two monoand two trivalent silver ions, which in effect are capable of "firing" electrons under certain conditions which willdestroy AIDS viruses, other pathogens and immune suppressing moieties (ISM), not only through the electrocutionmode, but also by a binding process which occurs simultaneously with electron firing, namely, binding andchelation of divalent silver, i.e., the resulting product of the electron transfer redox that occur when the monovalentsilver ions are oxidized and the trivalent ions are reduced in the crystal. The binding/chelation effect occurs atactive sites of the AIDS virus, pathogens and ISM. Because of the extremely minute size of a single molecule ofthis crystal, several million of these devices may be employed in concert to destroy a virus colony to purge a lifesupport system of ISM and pathogens with the consumption of only parts per trillion of the crystal devices. Thus anoptimum of 40 PPM of the devices by weight of human blood was found to be sufficient to completely obliterateAIDS. This concentration is slightly over double of the optimum concentration recommended in applicant'saforementioned U.S. patent for the destruction of the human AIDS virus in vitro. Other details concerning thestructure of the crystal and its mechanism against pathogens, the AIDS virus and ISM would analogously holdhere, and have already been further elucidated in said patent.The actual destruction of pathogens, ISM and the AIDS virus is effectuated by injection of a suspension of thesedevices in distilled or deionized water with a non-reacting electrolyte directly, i.e. intravenously, into thebloodstream. A single injection is all that is required under these conditions. Accordingly, humans injected in thismanner, upon being inspected after three weeks or more had elapsed and compared with similar humans that hadbeen given placebos, were completely cured of AIDS. The control group still manifested AIDS. Accordingly, thetetrasilver tetroxide device performed in concert with and in full conformity with the ultimate objects of thisinvention. Furthermore, three out of four wasting syndrome terminal patients and four out of the five candidiasisterminal patients were still alive in 1995 after a year and a half had elapsed from their initial injection. By that timeall the AIDS patients had been released from the clinic and allowed to return home.Other objects and features of the present invention shall become apparent to those skilled in the art when thepresent invention is considered in view of the accompanying examples. It should, of course, be recognized that the

accompanying examples illustrate preferred embodiments of the present invention and are not intended as ameans of defining the limits and scope of the present invention.EXAMPLE 1Five patients afflicted with AIDS of the candidiasis etiological category were segregated for Tetrasil treatment. Therationale for selecting them was based on facts presented in an article by Peter H. Duesberg and Brian J. Ellisonentitled "Is The AIDS Virus A Science Fiction?" (Policy Review, Summer 1990 pp. 40-51). Only the factualpresentations of the article were utilized and the hypothesis of the authors was ignored. The facts presented in thearticle related to the method of selecting AIDS patients based on the five aforementioned etiological subgroupstargeted by the CDC, and the evidence presented, that there is AIDS without HIV as well as with it so that an antiviral agent in most instances will not necessarily restore the immunity system.Evaluations with Tetrasil were conducted on AIDS patients at Lucha Contra el Sida, Comayaguela, Honduras. Thepatients two weeks prior to inoculation were removed from their AZT, AIDS therapy. Tetrasil was administered atapproximately 40 PPM of blood volume per patient as a suspension in a proprietary buffer solution (pH 6.5),supplied by Holipharm Corporation.The results of evaluations with candidiasis are tabulated in Table I under its disease category. All patientsevaluated were terminal. Some, however, were in moderate (m) condition and others in poor (p) as designated inthe Table. The I and F designations refer to initial and final values as shown. WBC indicates white cell blood count.The H column, following CD 8, indicates whether hepatomegaly occurred. This was an unfortunate consequence ofthe treatment which resulted in enlarged livers in all patients except the second one. Despite hepatomegaly, therewas no interference with liver function.The onset of hepatomegaly was not spontaneous and varied from patient to patient, being in the range of 4-16days.It should also be noted that shortly after injection of Tetrasil there were indications of fever (symbolized by T in theAg4 O4 column), sometimes accompanied by fatigue (F). The body temperature was invariably 38.5 C. (101.3 F.).This was indicative of restoration of the immune response of the body, since normally the body will destroypathogens when the immune system is functional by raising the temperature. The patient who died; first respondedfavorably to Diflucan, which previously gave no response. He was cured of his candidiasis, but unfortunatelysuccumbed to his previous body damage. All the other candidiasis syndrome people who previously did notrespond to the indicated medications subsequently responded after the Tetrasil treatment. Further evidence of therecovery of the AIDS patients manifested itself 30 days after the initial injection when white blood cell counts weretaken. They are shown in Table I under the WBC column, which gives the initial and final WBC. All candidiasispatients showed a dramatic increase in their white blood cell counts, indicative of the restoration of their immunitysystems.

EXAMPLE 2The above protocol of Example 1 was repeated with AIDS patients exhibiting wasting syndrome. The results oftheir treatment are tabulated in Table I under the disease category of said syndrome. It should be noted that two ofthe four wasting syndrome patients showed improved white blood counts. The female patient, whose conditionimproved from poor and terminal to be among the living, showed a decrease in the WBC. However, she showed anincrease in body temperature which was indicative of immune response. The test results indicate that one cannotrely on a single factor to indicate the demise of AIDS. The usual HIV marker CD 4 initial and final are irrelevant.ISM suppression appears to be more critical than the destruction of HIV. AIDS was suppressed, any permanentdamage that had been done to the patients in the course of their succumbing to AIDS was not obviously cured orcorrected by said crystal device treatment, rather said injury persisted and the patient was improved with respect toAIDS but still suffered from said permanent injury or impairment previously inflicted.TABLEI